Custom Lentivirus Packaging Services

Available envelopes for Lentiviral vector

VSV-G appeared to interact with an ubiquitous cellular receptor, a phospholipid component of the cell membrane, which conferred the ability of entry into multiple cell types tested and conferred high stability to the infectious vector particles.

Besides VSV-G, we supply you many different viral glycoproteins that have been incorporated into LVVs to improve their infectivity and confer them a more selective tropism.

* All the data mentioned above originates from the literature.

* Moreover, we can also provide lentivirus surface engineering services that can incorporate CD47, CD9, CD33, or CD329 into the lentivirus cell membrane.

Available Scales for Lentiviral vector producing

*The turnaround time only refers to the time for virus packaging.

*Titer detection is the infection titer of 293T, details need to be inquired

Highlights for LVV services

Integrated and Non-integrated system

• Conventional integrated lentivirus packaging system
• Integrase-deficient lentivirus packaging system, IDLV

Vpack System

• Inducible virus packaging system ('CuO' system)
• Patented system (WO 2022121849 A1)
• 10+ fold improvement in the yield

NK cell tropism lentivirus packaging

• With genetic modified envelope on the lentivirus
• >70% gene express efficiency in primary NK cells

Lentivirus infects cell types

Cases of LVV services

1. Piezo1 activation suppresses bone marrow adipogenesis to prevent osteoporosis by inhibiting a mechanoinflammatory autocrine loop

Published in Signal Transduction and Targeted Therapy

Institution: The University of Hong Kong

OBiO Contribution:

OBiO provided lentiviral vectors encoding shRNA against Lcn2 (Lenti‑shLcn2), scrambled shRNA (Lenti‑sc), and lentiviral constructs for Klf2 overexpression driven by the PDGFRα promoter. These tools enabled loss‑ and gain‑of‑function studies in bone marrow mesenchymal stem cells (BMMSCs), demonstrating that Piezo1 deficiency activates an autocrine Ccl2‑Lcn2 inflammatory loop and shifts BMMSC fate toward adipogenesis.

Signal Transduct Target Ther. 2025 Oct 28;10(1):357. doi: 10.1038/s41392-025-02455-w.

2. CSTF2‑impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer

Published in Cell Death & Differentiation

Institution: Sun Yat‑sen University

OBiO Contribution:

OBiO provided lentiviral vectors encoding sgRNAs targeting mouse Cstf2, Net1, Fug1, Cxcl10 and human CSTF2, along with Cas9, in a pLenti‑U6‑EFS‑NS‑Cas9‑2A‑Puro/Neo backbone. These lentiviral constructs enabled efficient CRISPR‑Cas9‑mediated gene knockout in KPC murine pancreatic cancer cells and human PANC‑1/CFPAC‑1 cell lines. Using this tool, the study demonstrated that CSTF2 in tumor cells suppresses CXCL10 expression and consequently impairs infiltration and anti‑tumor activity of innate αβ T cells, establishing CSTF2 as a key immune‑evasion driver and therapeutic target in pancreatic cancer.

Cell Death Differ. 2025 May;32(5):973-988. doi: 10.1038/s41418-025-01464-0.

3. YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti‑tumor immunity

Published in Nature Communications

Institution: University of Macau

OBiO Contribution:

OBio produced lentiviral vectors expressing shRNAs targeting human METTL3, IKZF1 and IKZF3 for gene knockdown in Jurkat cells. These lentiviral tools were used to manipulate the IKZF1/3 pathway in T cells, demonstrating that YTHDF2 sequesters IKZF1/3 to preserve CD8 T cell polyfunctionality and anti‑tumor immunity.

Nat Commun. 2024 Nov 5;15(1):9559. doi: 10.1038/s41467-024-53997-6.

FAQ of LVV services

What information do I need to provide for lentivirus packaging?

Researchers can provide either an existing lentiviral transfer plasmid or the gene sequence of interest. If vector construction is required, our team can assist with plasmid design, cloning, and validation prior to virus production.

What is the difference between lentivirus and AAV?

Lentiviral vectors integrate into the host genome and are commonly used for stable gene expression and cell engineering. AAV vectors generally remain episomal and are widely used for in vivo gene delivery. The optimal vector depends on the target tissue, duration of expression required, and study objectives.

Will the target protein invariably be upregulated or downregulated following overexpression or knocking down of the target gene?

Owing to post-translational regulatory mechanisms, and the uncertainty regarding the specificity of the target antibody, it is not always possible to detect an upregulation or downregulation of the protein at the protein level after overexpression or interference regulation of the cell. If the target antibody fails to detect the overexpression or knocking down, attempting to use qPCR or a tag antibody for detection could be an option.

Can Lentivirus be employed as conventional plasmids for overexpression?

Lentivirus can serve as conventional overexpression plasmids. However, due to the larger scaffold of Lentivirus, the entire plasmid is larger than that of a typical eukaryotic vector, which might influence the transfection efficiency in cells that are inherently difficult to transfect.

If exogenous gene expression is undetectable, what should be done?

First, exclude the possibility of infection or transfection efficiency problems based on the elements carried by the carrier, such as fluorescence efficiency of 80% or the use of antibiotics with corresponding eukaryotic resistance for screening. If it is still not detected, there may be the following reasons:

① The specificity of the target antibody is not good, and the protein has different cleavage forms, so the target protein cannot be detected by the use of the target antibody;

② The cell's own regulatory mechanism makes it impossible for the target protein to be overexpressed multiple times. It is suggested to replace the tag antibody or perform PCR to try detecting it.